OPERATING REVENUES $45,594 $177,888

Size: px

Start display at page:

Download "OPERATING REVENUES $45,594 $177,888"

Camron McCoy
5 years ago
Views:

1 SHANGHAI YUTONG PHARMA CO., LTD. STATEMENTS OF OPERATIONS AND ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) FOR THE TERMS ENDED Sep. 30, 2007 AND Sep. 30, 2006 (RESTATED (IN US $) (RESTATED) OPERATING REVENUES $45,594 $177,888 COST OF SALES Inventory, beginning of period 66,080 80,437 Research and development costs 119, ,270 Purchases 30,508 98,388 Inventory, end of period (104,903) (151,349) Total Cost of Sales 111, ,746 GROSS (LOSS) (66,062) 22,142 OPERATING EXPENSES Selling and promotion 9,943 - General and administrative fees 101,140 81,201 Consulting fees for stock 10,084 9,483 Bad debt expense (90,168) (142,797) Depreciation, amortization and impairment 97, ,809 Total Operating Expenses 128,159 91,696 (LOSS) BEFORE OTHER INCOME (EXPENSE) (194,221) (69,554) OTHER INCOME (EXPENSE) Other operating profit Interest income, net of expense (125,178) 18,440 Total Other Income (Expense) (125,178) 18,440 NET (LOSS) BEFORE PROVISION FOR INCOME TAXES (319,399) (51,114) Provision for Income Taxes - NET (LOSS) APPLICABLE TO COMMON SHARES $(319,399) $(51,114)

2 SHANGHAI YUTONG PHARMA CO., LTD. STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE YEARS ENDED Sep. 30, 2007 AND Common Accumulated Exchange Stock Deficit Reserve Total alance as of 31 ecember ,249,441 $(3,760,445) $3,488,996 et loss for the year ended ecember 31, (1,335,238) (1,335,238) alance December 31, 2003, as stated 7,249,441 (5,095,683) - 2,153,758 dditional paid-in capital 845, ,768 et loss for the year ended ecember 31, (797,932) (797,932) alance December 31, 2004, as stated 8,095,209 (5,893,615) - 2,201,594 et loss for the year ended ecember 31, 2005, - (604,081) (604,081) xchange serve 56,278 56,278 alance December 31, 2005, as stated 8,095,209 (6,497,696) 56,278 1,653,791 djustments the net loss for the ear before Dec.31, , ,628 et loss for the term ended EC. 31, (323,501) (323,501) xchange serve 74,166 74,166 alance DEC. 31, ,095,209 (6,494,569) $1,731,084

3 130,44 4 et loss for the term ended Sep. 0, (319,399) (319,399) xchange serve 68,949 68,949 alance Sep. 30, ,604,759 (6,813,968) 199,39 3 1,480,634

4 SHANGHAI YUTONG PHARMA CO., LTD. STATEMENTS OF CASH FLOWS FOR THE TERM ENDED Sep. 30, 2007 AND Sep. 30, 2006 (IN US $) (Restated) CASH FLOWS FROM OPERATING ACTIVITIES Net income/(loss) $(319,399) $(51,114) Adjustments to reconcile net income/(loss) to net cash from operating activities: Depreciation, amortization 257,997 Interest expense Exchange reserve 68,949 33,771 Changes in operating assets and liabilities: Accounts receivables 283, ,383 Inventories (38,823) 1,030 Accounta payable (221,139) (54,389) Prepaid expenses and other current assets (184,032) (494,540) Accrued and other current liablities 147,216 (158,035) Net cash flows from operating activities (5,687) (369,085) CASH FLOWS FROM INVESTING ACTIVITIES (Acquisitions) disposals of fixed assets (236,836) (277,965) Net cash provided by (used in) investing activities (236,836) (277,965) CASH FLOWS FROM FINANCING ACTIVITES Receipt of borrowings 140,342 1,274,345 Repayments of borrowings Cash payments for interest expenses (127,685) Additional capital Net cash flows from financing activities 140,342 1,146,660 Effect of foreign currency translation NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (102,181) 499,610 CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 114,136 54,057

5 CASH AND CASH EQUIVALENTS - END OF PERIOD $11, ,667 CASH PAID DURING THE YEAR FOR: Interest expense, net of amounts capitalized $(102,181) 499,610

6 Balance Sheet ASSETS Current Assets: Cash and cash equivalents $11,955 $114,136 Accounts receivable, net 2, ,224 Inventories 104,903 66,080 Prepaid expenses and other current assets 1,048, ,165 Total Current Assets 1,167,735 1,330,605 Fixed assets, net of depreciation and CIP 4,902,211 4,923,373 TOTAL ASSETS $6,069,946 $6,253,978 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) LIABILITIES Current Liabilities: Current postion of long-term debt $3,478,990 $3,346,268 Accounts payable and other current libilities 910, ,533 Total Current Liabilities 4,389,600 4,330,801 Long-term Liabilities: Long-term debt, net of current portion 199, ,093 Total Long-term Liabilities 199, ,093 Total Liabilities 4,589,312 4,522,894

7 STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock, - - Common stock- paid-in capital 8,095,209 8,095,209 Accumulated deficit (6,813,968) (6,494,569) Exchange reserve 199, ,444 Accumulated other comprehensive income (loss) Total Stockholders' Equity (Deficit) 1,480,634 1,731,084 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $6,069,946 $6,253,978

Unappropriated retained earnings (accumulated deficit) Total unappropriated retained earnings (accumulated deficit) 676, ,797 Total retained ear

Unappropriated retained earnings (accumulated deficit) Total unappropriated retained earnings (accumulated deficit) 676, ,797 Total retained ear Financial Statement Balance Sheet Accounting Title 2014/12/31 2013/12/31 Balance Sheet Assets Current assets Cash and cash equivalents Total cash and cash equivalents 1,183,185 1,177,682 Current bond investment